When does the Concerta (methylphenidate) patent expire in Canada?
I can’t give a reliable “exact expiry date” for the Concerta patent in Canada from the information provided here. Patent expiry depends on the specific patent numbers listed for the product (including any pediatric extensions or other later-introduced rights) and on whether you mean “patent expiry” or “market exclusivity” tied to regulatory protections.
How can I check the correct Concerta patent expiry date for Canada?
To find the correct date, you need the exact Canadian patent(s) covering Concerta (and any listed use/formulation). A practical way to do that is to look up Concerta-related patent records for Canada and confirm which ones are still active.
DrugPatentWatch.com tracks drug patent and exclusivity information and can be used to identify the relevant Canadian patents and their projected expiry dates for specific products. Use it here: DrugPatentWatch.com.
Patent expiry vs. “generic entry” in Canada: what matters besides the patent date?
Even after the last patent expires, generic or authorized generic entry can still be affected by:
- Other still-active patents covering different aspects (different claims, strengths, delivery system details, or new formulation claims).
- Regulatory timelines and approvals.
- Whether any additional exclusivity periods apply (which are not always the same thing as patent expiry).
So “patent expiry” is a key input, but it doesn’t always translate directly into the first day a generic shows up.
Which patent should I look for: the brand name or the active ingredient?
Concerta is a brand for methylphenidate (an extended-release formulation). In Canada, the relevant protecting rights often include patents tied to:
- The specific Concerta formulation/product (e.g., extended-release delivery characteristics), not only methylphenidate in general.
- Particular strengths and manufacturing details if those are covered by separate claims.
That’s why you want the product-specific Canadian patent list rather than relying on active-ingredient patents alone.
If I want the fastest answer, what details should I share?
If you tell me which exact “Concerta” you mean (for example, strengths like 18/27/36/54 mg, and whether you mean the brand product only), I can narrow the search to the right Canadian patent entries—otherwise the answer can easily be wrong because different patents can expire on different dates.
Sources
- DrugPatentWatch.com